CANANDAIGUA - For Leanne Bossert, the denials began in December 2020. I was shocked, I was scared, and I went away from my other kids and I cried, said Bossert, 38. I didn’t even know it was something that would happen.
Her health insurance company, Excellus BlueCross BlueShield, denied coverage of proton radiation therapy treatment for her two brain tumors. As she admitted in a phone interview, the initial denial was jarring, as she thought the most difficult part of this scenario would be correlating all my records for the treatment, in addition to working out childcare needs for her four children during the six-week treatment.
Negative Results When Immunotherapy Was Added Onto Radiation medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
CANANDAIGUA, NY For Leanne Bossert, the denials began in December 2020. I was shocked, I was scared, and I went away from my other kids and I cried, said Bossert, 38. I didn’t even know it was something that would happen.
Her health insurance company, Excellus BlueCross BlueShield, denied coverage of proton radiation therapy treatment for her two brain tumors. As she admitted in a phone interview, the initial denial was jarring, as she thought the most difficult part of this scenario would be correlating all my records for the treatment, in addition to working out childcare needs for her four children during the six-week treatment.
Rankings Of Most Common And Deadly Cancer Types Will Shift Over Next Two Decades prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Date Time
Excellent outcomes reported for first targeted frontline therapy for high-risk pediatric Hodgkin lymphoma
(From left) First and corresponding author Monika Metzger, M.D., Departments of Oncology and Global Pediatric Medicine; co- senior author Matthew Krasin, M.D., Department of Radiation Oncology; and co-senior author Melissa Hudson, M.D., Cancer Survivorship Division director.
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma. The study showed that the addition of brentuximab vedotin achieved excellent outcomes, reduced side effects, and allowed for reduced radiation exposures.
The study was the result of work by a multi-site consortium dedicated to pediatric Hodgkin-lymphoma. Collaborating institutions include St. Jude Children’s Research Hospital, Stanford University School of Medicine, Dana-Farber Cancer Institute, Massachusetts General Hospital, Maine Children’s Cancer P